BiVictriX Therapeutics (LON:BVX) Trading Up 17.6%

BiVictriX Therapeutics Plc (LON:BVX) shot up 17.6% during trading on Monday . The company traded as high as GBX 10 ($0.13) and last traded at GBX 10 ($0.13). 1,538,020 shares traded hands during trading, an increase of 1,320% from the average session volume of 108,326 shares. The stock had previously closed at GBX 8.50 ($0.11).

BiVictriX Therapeutics Stock Performance

The firm’s fifty day moving average price is GBX 10.02 and its 200 day moving average price is GBX 11.14. The firm has a market cap of £8.25 million, a P/E ratio of -250.00 and a beta of -0.73. The company has a debt-to-equity ratio of 8.81, a quick ratio of 7.49 and a current ratio of 4.40.

Insider Activity at BiVictriX Therapeutics

In related news, insider Robert Edward Hawkins acquired 20,000 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was purchased at an average cost of GBX 7 ($0.09) per share, for a total transaction of £1,400 ($1,872.66). 42.56% of the stock is currently owned by corporate insiders.

BiVictriX Therapeutics Company Profile

BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours.